- A Look at Barclays PLC (BCS) After 4.1% Decline -- GF Value $16.86 vs Price $22.73
May 12, 2026 · gurufocus.com
On May 12, 2026, Barclays PLC (BCS) shares fell 4.1% to $22.73 amid a broader trend of declining prices for the stock over the past month. The shares have witne
- Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference
May 12, 2026 · prnewswire.com
LAVAL, QC, May 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that members of company management will participate in a fireside chat at the Barclays 30th Annual Leveraged Finance Conference in Austin, Texas on Tuesday, May 19, 2026. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website.
- BAUSCH HEALTH TO PARTICIPATE IN BARCLAYS 30TH ANNUAL LEVERAGED FINANCE CONFERENCE
May 12, 2026
LAVAL, QC, MAY 12, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) TODAY ANNOUNCED THAT MEMBERS OF COMPANY MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE BARCLAYS 30TH ANNUAL LEVERAGED FINANCE CONFERENCE IN AUSTIN, TEXAS ON TUESDAY, MAY 19, 2026. A LIVE AUDIO WEBCAST OF THE EVENT WILL BE ACCESSIBLE ON THE INVESTOR RELATIONS SECTION OF BAUSCH HEALTH'S WEBSITE.
- FRN Variable Rate Fix
May 12, 2026
LONDON, May 12, 2026--(BUSINESS WIRE)--
As Agent Bank, please be advised of the following rate determined on: 5/12/2026 Issue ¦ Barclays PLC Series 283 EUR 1,250,000,000 FRN Due in May 2029 ISIN Number ¦ XS3069319542 ISIN Reference ¦ 306931954 Issue Nomin EUR ¦ 1250000000 Period ¦ 5/14/2026 to 8/14/2026 Payment Date 8/14/2026 Number of Days ¦ 92 Rate ¦ 3.352 Denomination EUR ¦ 1000 ¦ 1250000000 ¦ Amount Payable per Denomination ¦ 8.57 ¦ 10712500 ¦ Bank of New York Rate Fix Desk Telephone ¦ 44 1202 689580 Corporate Trust Services Facsimile ¦ 44 1202 689601
View source version on businesswire.com: https://www.businesswire.com/news/home/20260512063838/en/
Contacts
Bank of New York Mellon
View Comments
- Barclays Just Hiked Bloom Energy Price Target to $254: AI Data Center Power Story Just Got Bigger
May 12, 2026 · 247wallst.com
Barclays just turned more constructive on the AI data center power story.
- European Growth Companies With High Insider Ownership
May 12, 2026
The European market has experienced a volatile but ultimately positive week, with the pan-European STOXX Europe 600 Index showing modest gains amid easing geopolitical tensions and strong corporate earnings. However, looming threats of increased tariffs from the U.S. have added pressure to the markets, creating an environment where insider ownership can be a reassuring factor for investors looking at growth companies. In such conditions, stocks with high insider ownership might offer additional confidence to investors due to the alignment of interests between company insiders and shareholders.
Top 10 Growth Companies With High Insider Ownership In Europe
Name Insider Ownership Earnings Growth KebNi (OM:KEBNI B) 11.8% 82.7% Hacksaw (OM:HACK) 13.2% 24.8% Envipco Holding (ENXTAM:ENVI) 19.5% 46.5% Elliptic Laboratories (OB:ELABS) 19.8% 125.1% Dellia Group (OB:DELIA) 29.9% 63.7% CTT Systems (OM:CTT) 17.4% 47.1% Clavister Holding AB (publ.) (OM:CLAV) 18% 83.1% Circus (XTRA:CA1) 21.9% 84.8% Bonesupport Holding (OM:BONEX) 10.3% 34.5% Bergen Carbon Solutions (OB:BCS) 11.9% 56.9%
Click here to see the full list of 214 stocks from our Fast Growing European Companies With High Insider Ownership screener.
Let's review some notable picks from our screened stocks.
Trifork Group
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Trifork Group AG offers information technology and business services across several countries including Switzerland, Denmark, the United Kingdom, the Netherlands, and the United States, with a market cap of DKK1.70 billion.
Operations: Trifork Group AG's revenue segments are derived from providing IT and business services across various international markets, including Switzerland, Denmark, the UK, the Netherlands, and the US.
Insider Ownership: 19.9%
Trifork Group is experiencing significant earnings growth, forecasted at 23.2% annually, outpacing the Danish market. Despite a modest revenue increase of 7.8%, its insider ownership aligns with strategic leadership changes and product innovations like Tiris Messenger and Synq, aimed at expanding digital sovereignty and operational efficiency. Recent financials show improved net income to EUR 2.99 million in Q1 2026 from EUR 0.649 million a year prior, underscoring strong growth potential amidst competitive valuations below fair value estimates.
Dive into the specifics of Trifork Group here with our thorough growth forecast report. In light of our recent valuation report, it seems possible that Trifork Group is trading behind its estimated value.CPSE:TRIFOR Earnings and Revenue Growth as at May 2026
Humble Group
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Humble Group AB (publ) is involved in the development, production, and distribution of fast-moving consumer goods both in Sweden and internationally, with a market cap of SEK3.27 billion.
Story Continues
Operations: The company's revenue is primarily derived from four segments: Future Snacking (SEK1.31 billion), Sustainable Care (SEK2.30 billion), Quality Nutrition (SEK1.68 billion), and Nordic Distribution (SEK3.10 billion).
Insider Ownership: 26.5%
Humble Group shows promising growth potential with forecasted earnings growth of 55.41% annually, surpassing the Swedish market average. Despite a decrease in profit margins from 1.2% to 0.4%, recent Q1 results reveal improved net income of SEK 28 million and stable sales growth to SEK 1,994 million. The company secured a new SEK 2 billion credit facility, enhancing financial stability for future expansion while insiders have increased their holdings recently, indicating confidence in its strategic direction.
Navigate through the intricacies of Humble Group with our comprehensive analyst estimates report here. Upon reviewing our latest valuation report, Humble Group's share price might be too optimistic.OM:HUMBLE Ownership Breakdown as at May 2026
AlzChem Group
Simply Wall St Growth Rating: ★★★★☆☆
Overview: AlzChem Group AG, with a market cap of €1.67 billion, develops, produces, and markets a variety of chemical specialties across Germany, the European Union, other parts of Europe, Asia, the NAFTA region, and internationally.
Operations: Revenue Segments (in millions of €): Specialty Chemicals €200.50, Basic Chemicals €150.75, and Agrochemicals €100.25.
Insider Ownership: 15.5%
AlzChem Group demonstrates solid growth prospects with earnings forecasted to grow by 18.7% annually, outpacing the German market. Recent Q1 results showed increased sales of €148.65 million and net income of €17.96 million, reflecting strong operational performance. The company's revenue is expected to grow at 11.2% per year, driven by volume effects in Specialty Chemicals, while trading significantly below its estimated fair value suggests potential undervaluation despite no recent insider trading activity noted.
Click here and access our complete growth analysis report to understand the dynamics of AlzChem Group. Our valuation report here indicates AlzChem Group may be undervalued.XTRA:ACT Ownership Breakdown as at May 2026
Seize The Opportunity
Click this link to deep-dive into the 214 companies within our Fast Growing European Companies With High Insider Ownership screener. Seeking Other Investments? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include CPSE:TRIFOR OM:HUMBLE and XTRA:ACT.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- 3 European Growth Stocks With Up To 36% Insider Ownership
May 12, 2026
In recent weeks, the pan-European STOXX Europe 600 Index has experienced modest gains amid easing geopolitical tensions and strong corporate earnings, despite pressures from potential U.S. tariff increases on EU goods. As investors navigate this landscape, growth companies with high insider ownership can be appealing due to their potential for alignment of interests between management and shareholders, offering a unique edge in today's market environment.
Top 10 Growth Companies With High Insider Ownership In Europe
Name Insider Ownership Earnings Growth KebNi (OM:KEBNI B) 11.8% 82.7% Hacksaw (OM:HACK) 13.2% 24.8% Envipco Holding (ENXTAM:ENVI) 19.5% 46.5% Elliptic Laboratories (OB:ELABS) 19.8% 125.1% Dellia Group (OB:DELIA) 29.9% 63.7% CTT Systems (OM:CTT) 17.4% 47.1% Clavister Holding AB (publ.) (OM:CLAV) 18% 83.1% Circus (XTRA:CA1) 21.9% 84.8% Bonesupport Holding (OM:BONEX) 10.3% 34.5% Bergen Carbon Solutions (OB:BCS) 11.9% 56.9%
Click here to see the full list of 214 stocks from our Fast Growing European Companies With High Insider Ownership screener.
Underneath we present a selection of stocks filtered out by our screen.
Oryzon Genomics
Simply Wall St Growth Rating: ★★★★★☆
Overview: Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS, oncology, and hematology disorders, with a market cap of €216.73 million.
Operations: The company generates its revenue primarily from the biotechnology segment, amounting to €10.93 million.
Insider Ownership: 13.9%
Oryzon Genomics shows promising growth potential, with earnings forecast to grow 51.67% annually and revenue expected to increase by 47.9% per year, outpacing the Spanish market. Despite recent net losses of EUR 2.61 million for 2025, sales improved significantly from EUR 7.36 million to EUR 10.93 million year-over-year. The company is advancing its clinical pipeline with significant developments in iadademstat trials and strategic leadership appointments enhancing its CNS programs' capabilities.
Take a closer look at Oryzon Genomics' potential here in our earnings growth report. Our comprehensive valuation report raises the possibility that Oryzon Genomics is priced higher than what may be justified by its financials.BME:ORY Ownership Breakdown as at May 2026
Med Life
Simply Wall St Growth Rating: ★★★★★☆
Overview: Med Life S.A. is a private healthcare provider offering integrated medical services through its clinics and hospitals in Romania, with a market cap of RON6.35 billion.
Operations: The company's revenue is primarily derived from its clinics (RON1.18 billion), hospitals (RON883.26 million), corporate services (RON306.92 million), laboratories (RON352.04 million), pharmacies (RON78.40 million), and stomatology services (RON122.21 million).
Story Continues
Insider Ownership: 36.5%
Med Life demonstrates potential as a growth company with high insider ownership, despite challenges. Its revenue is forecast to grow at 9.5% annually, outpacing the Romanian market average of 5.2%. However, profit margins have declined from 0.9% to 0.4%, and net income fell to RON 11.6 million in 2025 from RON 25.04 million the previous year. Earnings are expected to grow significantly at an annual rate of over 62%, though interest coverage remains a concern.
Click here and access our complete growth analysis report to understand the dynamics of Med Life. Our expertly prepared valuation report Med Life implies its share price may be too high.BVB:M Earnings and Revenue Growth as at May 2026
Circus
Simply Wall St Growth Rating: ★★★★★★
Overview: Circus SE is a technology company that develops and delivers autonomous solutions for the food service market, with a market cap of €214.73 million.
Operations: The company generates its revenue primarily from the Industrial Automation & Controls segment, amounting to €0.88 million.
Insider Ownership: 21.9%
Circus SE is positioned for significant growth, with revenue projected to expand 45.5% annually, surpassing the German market's average. Despite past shareholder dilution and a volatile share price, Circus is expected to achieve profitability within three years and boasts a high forecasted return on equity of 105.7%. Recent strategic alliances and successful financing initiatives underscore its expanding deployment of AI robotics in defence sectors, including contracts with the German and Lithuanian armed forces.
Navigate through the intricacies of Circus with our comprehensive analyst estimates report here. According our valuation report, there's an indication that Circus' share price might be on the expensive side.XTRA:CA1 Ownership Breakdown as at May 2026
Next Steps
Embark on your investment journey to our 214 Fast Growing European Companies With High Insider Ownership selection here. Want To Explore Some Alternatives? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 15 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include BME:ORY BVB:M and XTRA:CA1.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- FTSE 100 Index drops as Barclays, NatWest, and Lloyds sink amid 2 key risks
May 12, 2026 · invezz.com
The FTSE 100 Index retreated for the fourth consecutive day, reaching its lowest level since March 30th. It has dropped by over 6.30% from its highest point this year as geopolitical risks jumped.
- Barclays Investor News: If You Have Suffered Losses in Barclays PLC (NYSE: BCS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
May 12, 2026
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) --
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Barclays PLC (NYSE: BCS) resulting from allegations that Barclays may have issued materially misleading business information to the investing public.
SO WHAT: If you purchased Barclays securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=23523 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.
WHAT IS THIS ABOUT: On February 27, 2026, Reuters published an article entitled “Wall Street hit by UK mortgage lender collapse, raising fears of more credit ‘cockroaches.'” The article stated that lenders were “rocked by the implosion of little-known UK mortgage provider Market Financial Solutions Ltd [“MFS”], fueling concerns about wider losses among banks and reviving warnings of more “cockroaches” in the booming private credit industry.” It further stated that another publication “reported Barclays has a 600 million pound ($809.70 million) exposure to MFS.”
On this news, Barclays American Depositary Shares (“ADS”) fell 3.99% on February 27, 2026, and 2.3% on March 2, 2026.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com
- Barclays Investor News: If You Have Suffered Losses in Barclays PLC (NYSE: BCS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
May 11, 2026 · globenewswire.com
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Barclays PLC (NYSE: BCS) resulting from allegations that Barclays may have issued materially misleading business information to the investing public.
